MAPK1 and breast cancer: The decision to test MAPK1/ERK2 only in the RT-PCR assays was based on reports that show MAPK3/ERK1 association with a better prognosis and its role in modulating the YAP1 signaling pathway, indicating that MAPK3 is a negative regulator of breast cancer development.